Samji, Naga Swetha
Verma, Rajanshu
Keri, Krishna Chaitanya
Singal, Ashwani K.
Ahmed, Aijaz
Rinella, Mary
Bernstein, David
Abdelmalek, Manal F.
Satapathy, Sanjaya K. http://orcid.org/0000-0003-0153-2829
Article History
Received: 6 January 2019
Accepted: 2 July 2019
First Online: 16 July 2019
Compliance with Ethical Standards
:
: Dr. Abdelmalek reports no conflicts of interest related to the submitted work. Dr. Abdelmalek reports receiving grants awarded to her institution from NIH/NIDDK, Gilead, Conatus, Intercept, NGM, BMS, Boeringher-Ingelheim, Madrigal, Inventiva, Enanta, Novartis, Allergan, Target-NASH, Progenity, TaiwanJ, Poxel, Novo Nordisk, and Celgene. She participated in Speakers Bureau for Alexion, Simply Speaking NASH, MedScape, iHep NASH, and Clinical Care Options and is on the Scientific Advisory Board for NGM, BMS, TaiwanJ, Pfizer, Madrigal, Prometic, and SanoNASH. Dr. Sanjaya Satapathy reports no conflicts of interest related to the submitted work. Dr. Satapathy reports receiving grants from Gilead Sciences and participated in Speakers Bureau, Advisory Board of Gilead Sciences, received grants from Intercept Pharmaceuticals and participated in the Speakers Bureau, Advisory Board of Intercept Pharmaceuticals, received grants from Shire, grants from Conatus, grants from Bayer, and participated in the Speakers Bureau of Alexion, received grants from Dova and participated in the Speakers Bureau, and Advisory Board of Dova, received grants from Genfit, grants from Exact Sciences, and participated in the Advisory Board of Abbvie, outside the submitted work. Dr. Aijaz Ahmed, Dr. Samji Swetha, Dr. Ashwani Singal, Dr. Krishna Chaitanya Keri, Dr. Rajanshu Verma, and Dr. Manal Abdelmalek report no conflicts of interest related to the submitted work. Dr. David Bernstein reports no conflicts of interest related to the submitted work. He reports consulting/Ad Boards for Abbvie, Gilead, Dova, Shinoigi, Mallinkropt, Intercept, and reports having received research support from Abbvie, Gilead, Dova, Conatus, CymBay, Merck, BI, NovoNordisk, Novartis. Dr. Rinella reports no conflicts of interested related to this manuscript. She does consulting for the following pharmaceutical companies: Intercept, Gilead, NGM, BMS, Enanta, Novartis, Genfit, Immuron, Cymabay, Merck, Gelesis, Metacrine, Viking, Madrigal, Allergan, Thetis, Fractyl, 3vBio. She has received independent research funding from Novartis. She has no stock ownership in any company for whom she consults and is on no speakers bureaus.